Biosimilar Growth Hormones Market Report 2025

This Biosimilar Growth Hormones market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The biosimilar growth hormones market size has grown strongly in recent years. It will grow from $0.76 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising demand for growth hormones, patent expirations, clinical evidence, and increasing clinical trials.

The biosimilar growth hormones market size is expected to see strong growth in the next few years. It will grow to $1.19 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to pediatric growth disorders, expanding indications, increase in the diagnosis, and increased awareness of biosimilar options. Major trends in the forecast period include pediatric-focused biosimilars, biosimilar combinations, dosing convenience, biosimilar combinations, and dosing convenience.

The rising incidence of growth hormone deficiency among children is propelling the expansion of the global biosimilar growth hormone market. This deficiency results from damage to the pituitary gland or hypothalamus, which may stem from a congenital abnormality present before birth or an issue that arises during or after birth (acquired). For example, data released in September 2023 by Hormones Australia, a branch of the Endocrine Society of Australia (ESA) specializing in endocrine-related diseases, estimates that growth hormone deficiency affects approximately 2 to 3 in every 10,000 people. Consequently, the increase in children affected by growth deficiencies is driving demand within the biosimilar growth hormone industry.

The rising prevalence of chronic diseases is anticipated to drive the growth of the biosimilar growth hormone market. Chronic diseases are persistent health issues that are usually incurable but can be managed effectively. These enduring conditions, while not curable, can benefit from management through the use of biosimilar growth hormones, which have shown effectiveness in treating chronic illnesses, particularly in children with growth disorders and chronic kidney disease. For example, in February 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health organization, reported an increase in Americans living with multiple chronic conditions, with 42% managing two or more conditions and 12% dealing with five or more. Thus, the growing prevalence of chronic diseases is expected to further boost the biosimilar growth hormone market in the coming years.

Leading companies in the biosimilar growth hormones market are developing innovative solutions, such as human growth hormone treatments, to improve the effectiveness and affordability of therapies for growth hormone deficiencies. Growth hormone solutions encompass medical treatments or supplements aimed at stimulating or replacing human growth hormone (HGH) in the body, addressing growth deficiencies and, in some cases, anti-aging needs. For example, in June 2023, Pfizer Inc., a U.S.-based pharmaceutical company, and OPKO Health Inc., a healthcare company also based in the U.S., received approval from the U.S. Food and Drug Administration (FDA) for NGENLA (somatrogon-ghla). This once-weekly injectable growth hormone treatment is designed for pediatric patients with growth hormone deficiency (GHD), offering a long-acting alternative to daily injections that can improve adherence and convenience for both patients and caregivers. The FDA’s approval, based on clinical studies showing its safety and efficacy, represents a significant advancement in growth hormone therapy.

Leading companies in the biosimilar growth hormones market are introducing new products, such as growth hormone therapies, to enhance profitability in the industry. Growth hormone therapy involves treatments that supplement or stimulate growth hormone production to aid growth and development, especially in children with hormone deficiencies. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based pharmaceutical company, launched SKYTROFA (lonapegsomatropin) in Germany. Approved for use across the European Union, this once-weekly treatment is designed for children and adolescents aged 3 to 18 years who experience growth failure due to insufficient natural growth hormone production (growth hormone deficiency, or GHD).

In October 2023, the US-based biotechnology company Amgen completed the acquisition of Horizon Therapeutics plc for a substantial $27.8 billion. This strategic move aligns with Amgen's overarching goal of providing innovative and impactful medications to patients dealing with severe illnesses. The acquisition notably includes Horizon's pharmaceutical portfolio, encompassing Tepezza, designed to address thyroid eye disease, Krystexxa, targeting chronic refractory gout, and Uplizna, intended for neuromyelitis optica spectrum disorder.

Biosimilar growth hormone is a peptide hormone vital for stimulating cellular regeneration, cell division, and overall growth in humans and other organisms. Its significance lies in its role in advancing human development, serving as a targeted mitogen affecting specific cell types.

These hormones are administered through various routes such as intravenous, subcutaneous, intramuscular, and oral methods. Intravenous administration involves the injection of fluids, medications, or nutrients directly into a patient's vein. Applications for biosimilar growth hormones encompass treating conditions like growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, among others. These treatments are available through diverse distribution channels including hospital and retail pharmacies, online pharmacy platforms, and specialty clinics.

The biosimilar growth hormone market research report is one of a series of new reports that provides biosimilar growth hormone market statistics, including biosimilar growth hormone industry global market size, regional shares, competitors with a biosimilar growth hormone market share, detailed biosimilar growth hormone market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar growth hormone industry. This biosimilar growth hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the biosimilar growth hormones market include Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation.

North America was the largest region in the biosimilar growth hormone market in 2024. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biosimilar growth hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar growth hormone market consists of sales of teriparatide, follitropin alfa, insulin, and somatropin. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.